Latest Share Purchase Plans News

Greenwing Resources has successfully completed its equity raising program, placing the shortfall from its Share Purchase Plan and an additional placement due to strong investor demand. This capital boost strengthens the company’s position as it advances its lithium and graphite projects.

Silex Systems Limited has announced a Share Purchase Plan (SPP) aiming to raise up to $15 million, offering existing eligible shareholders new shares at a price capped at $3.90 or a 2% discount to recent trading prices. This follows a $130 million institutional placement and supports key commercialisation projects in uranium enrichment.

Miramar Resources has extended its Share Purchase Plan closing date to 27 August 2025, giving shareholders more time to invest at a 20% discount as the company awaits critical exploration results.

Centaurus Metals has raised $23 million through an institutional placement and share purchase plan to advance its Jaguar Nickel Sulphide Project in Brazil towards a Final Investment Decision in early 2026.

Carnegie Clean Energy launches a $3 million Share Purchase Plan to fuel commercialisation of its wave and MoorPower technologies, capitalising on growing global momentum in ocean energy.

RBR Group has successfully closed its Share Purchase Plan, raising $261,000 from shareholders, while initiating efforts to place a $329,000 shortfall over the coming months.

Carnegie Clean Energy Limited has launched a $3 million Share Purchase Plan offering eligible shareholders in Australia and New Zealand new shares at a 14% discount to the last closing price. The offer opens mid-August and closes in early September, aiming to bolster capital without requiring shareholder approval.

Fat Prophets Global Contrarian Fund has announced a Share Purchase Plan allowing eligible shareholders in Australia and New Zealand to buy up to $30,000 in shares without brokerage fees. The move aims to increase fund size and trading liquidity ahead of potential broker coverage.

Euro Manganese Inc. has bolstered its development of the Chvaletice Manganese Project with new financing and critical regulatory approvals, while progressing offtake discussions amid ongoing market uncertainties.

Euro Manganese Inc. reported a $12.8 million loss for the nine months ended June 30, 2025, while securing $11.1 million in equity financing and amending its $20 million convertible loan facility. The company highlights ongoing funding risks as it advances its manganese projects.

Anatara Lifesciences reported a 35% rise in net loss to $1.95 million for FY25, following pivotal Phase II trial results for its GaRP product that missed the primary efficacy endpoint but showed promising secondary benefits. The company is advancing commercialisation efforts and launching a new anti-obesity project amid tightened cash reserves.

Atomo Diagnostics has successfully placed $416,611.77 from its Share Purchase Plan shortfall, bolstered by a recent US order from Lumos Diagnostics. This capital injection strengthens Atomo’s position as it scales up production of its Pascal cassettes.